AI
Sunday, August 13, 2023 3:35:40 PM
icon-fall
19%
Shares of Arcturus Therapeutics traded down ~19% on Tuesday after the company announced4 lower-than-expected revenue and earnings for the second quarter. According to management, revenue declined in response to the termination of two agreements, one with Vinbiocare and another with the Israeli Ministry of Health. Arcturus Therapeutics develops mRNA-based vaccines and therapeutics for the treatment of infectious and rare genetic diseases.
I am writing a book, American Cars of 1958. Check often for the latest addition. https://investorshub.advfn.com/American-Cars-of-1958-37252/
Recent ARCT News
UAV Corp. (UMAV) Reduces Authorized Shares by 1.2 Billion, Demonstrating Commitment to Shareholders; New Authorized Share Count Approved at 800 Million • UMAV • Dec 17, 2024 12:00 PM
Avant Technologies and Ainnova Secure Advanced AI Algorithms for Early Detection of Four Additional Diseases in the U.S. • AVAI • Dec 17, 2024 8:00 AM
North Bay Resources Announces MET Results of 97% Gold Recovery with Upgrade to 11.2 Ounces per Ton Concentrate, Fran Gold Project; Completes 120 Ton Winter Ore Shipment • NBRI • Dec 16, 2024 9:00 AM
Mass Megawatts Announces the Financial Reporting Status Being Current as of Today • MMMW • Dec 16, 2024 8:18 AM
VAYK Renewed JV to Renovate Historic Landmark into "Most Sought-after Airbnb Place" in Downtown Atlanta • VAYK • Dec 12, 2024 9:36 AM
Silexion Is Addressing the MOST COMMON Human Cancer Gene Mutation With RNAi; Recent M&As in the Field Were for Tens of Billions - $SLXN • SLXN • Dec 11, 2024 9:22 AM
